Key Highlights

● Revenue fell as Harvest left consolidated results

● Gross Margin widened and Net Income turned slightly positive

● Georgia traffic surged after a state program expansion

● A large disputed tax Liability remains on the balance sheet

Trulieve Cannabis Corp. (NYSE:TRLV), one of the most closely followed US cannabis operators, reported third-quarter results from Tallahassee, Florida, showing how the company looks after restructuring itself around medical marijuana. Revenue fell from the prior-year quarter and from the preceding quarter, gross margin widened, and net income attributable to common shareholders turned narrowly positive after a loss a year earlier.

The direction of those figures needs context, because the comparison is not like for like. The quarter includes only Trulieve's medical operations, while earlier periods include Harvest's mixed medical and adult-use business. Trulieve deconsolidated Harvest in early June, so a share of the decline reflects a change in reporting scope. The release itself flags this difference in its notes.

Chief executive Kim Rivers tied the period to federal policy, saying: "State licensed medical marijuana rescheduling unlocked major milestones including DEA registration." She also cited the removal of a federal tax burden and the company's move to the New York Stock Exchange, and pointed to Georgia and Texas as meaningful expansion opportunities.

Reading the Revenue Decline Correctly

Reported revenue declined by a rate of about one-fifth from the prior-year quarter. Retail remained the overwhelming source of sales. Market data, in its coverage of the results, attributed the decline to the June restructuring and reported that on a comparable medical-only basis revenue increased modestly from the second quarter. It also reported that customer traffic and products sold were up.

That comparable view resolves an apparent conflict in the figures. The company's reported second-quarter revenue, which includes a period of Harvest operations before the June deconsolidation, is well above the third-quarter figure. The medical-only comparison points the other way, showing sequential growth. Both are accurate, but they measure different perimeters, and only the second indicates the direction of the retained business.

Adjusted EBITDA fell from the prior year but rose as a share of revenue, reaching a higher margin than a year earlier. It was also lower than in the previous quarter, when part of the period still included Harvest.

The company's investor materials and market data also described guidance. Fourth-quarter revenue is expected to rise by a low single-digit rate from the third quarter. Trulieve also guided to a substantial full-year Operating Cash Flow figure and increased the upper limit of its Capital spending plan, directing part of that Investment toward markets including Georgia and Texas.

Margin, Taxes and a Thin Bottom Line

Gross margin improved by several points from the prior-year quarter. Operating expenses fell by a high-teens rate, and income from operations was nearly flat from a year earlier, despite the lower revenue base. That combination explains why profitability measures improved while revenue fell.

Tax played a large role. The provision for income taxes roughly halved from the prior year. According to market data, the company attributes the decline to no longer applying the federal trafficking deduction rule to its medical marijuana operations this year. The investor presentation states that the third-quarter tax expense included ordinary tax and interest on an uncertain tax position, but no liability under that rule.

The profit remains modest. Net income attributable to common shareholders was close to break-even, and GAAP Diluted Earnings per Share from continuing operations were reported at essentially zero. Adjusted net income was stronger, reversing a loss from a year earlier, because it excludes certain items. Net interest expense and Trulieve's share of a net loss at Harvest, now reported under the Equity method, also weighed on the bottom line.

The year-to-date picture looks very different. The accounting loss from the Harvest deconsolidation, recorded in the second quarter, produced a large net loss for the year to date. Goodwill and intangible assets on the Balance Sheet fell substantially from the end of last year, and total equity declined as well. The loss was an accounting event tied to removing the Business from the consolidated statements.

Georgia and Texas as the Growth Case

Georgia supplied the quarter's most striking operating data. The state expanded its medical program at the start of July, adding qualifying conditions and allowing flower and vape products. Trulieve said its Georgia traffic multiplied many times over following the change, and it opened a new dispensary in Dunwoody, with additional sites approved. The presentation describes patient counts in the state rising sharply since the start of the year.

The company holds one of the larger production licenses in Georgia and operates a cultivation campus in Adel. The state's program also allows distribution through independent pharmacies, a model the company describes as unique to Georgia, and Trulieve said that distribution resumes with DEA registration. New products launched in the state include Modern Flower and Roll One, and the company said those brands accounted for more than half of units sold, though it did not break out revenue from the Georgia expansion.

Texas is earlier in its development. Trulieve received a conditional license in December and expects final licensing this year. The company's presentation describes an expanding patient base, no cap on cultivation capacity, and an environment in which telehealth access and vape products are permitted. It also notes that a larger group of operators will be licensed in that market, so competition will be a factor.

Baked In, a newsletter, had earlier highlighted Georgia and Texas as the main drivers of the growth thesis. Separately, Trulieve closed a perpetual, royalty-free license for Alien Labs and Connected products in Florida and Texas during the quarter. A company release summarized by Market commentary said the Texas launch depends on final licensure and regulatory approvals, so any contribution remains tied to that process.

Georgia's rule change is broad as well as recent. The Baked In newsletter described the state's new law, signed by the governor and known as the Putting Georgia's Patients First Act, as removing severity requirements for qualifying conditions and adding a range of new diagnoses. That account, published before the change took effect, cited an estimate of a much larger eligible population, though it attributed the estimate to an executive order from a governor of another state, an apparent error that makes the projection unreliable. The patient figures in Trulieve's presentation are the firmer measure, and they show the registered base growing quickly.

Florida Remains the Foundation

Florida remains the core of the company. Trulieve operates the large majority of its dispensaries there, holds a leading retail position in the state's medical market, and reports substantial shares of flower and oil sales. The presentation describes Florida as the largest US medical marijuana market. It also says Trulieve stores sold notably more flower and oil per location during the quarter than the market average.

The company opened a dispensary in Marco Island during the quarter and continues to operate a large indoor cultivation Facility in Jefferson County. Outside Florida and Georgia, its consolidated medical operations cover Pennsylvania and West Virginia, with conditional approvals noted in Alabama and Texas. Trulieve said it sold into the large majority of Pennsylvania dispensaries in the period and reported a loyalty program with a substantial member base.

Harvest's mixed medical and adult-use stores in Arizona, Ohio, Connecticut and Maryland now sit outside the consolidated figures. The presentation states that an independent third-party investor controls Harvest, while Trulieve retains a large economic interest. The structure leaves the reported business as medical-only, which has specific implications for its federal status under the April order.

Florida also remains a medical-only state, a point Baked In highlighted: a recreational ballot amendment won majority support in the last attempt but fell short of the required threshold. The newsletter described the state's limited-license structure and vertical integration requirement as a competitive barrier. Trulieve's presentation lists support for state expansion in Florida among its focus areas, alongside Georgia, Pennsylvania and Texas. It also says customer retention in its medical-only markets remained high during the quarter.

The Federal Backdrop and the Unresolved Tax Liability

The policy context comes from the Justice Department's April order. A Sheppard Mullin summary on JD Supra explains that it moved FDA-approved products and marijuana covered by a state medical license into Schedule III, and created an expedited DEA registration path for state-licensed operators. It adds that the trafficking deduction rule applies only to more tightly scheduled substances, which would remove that limitation for state-licensed medical operators.

The same summary sets limits. Adult-use cannabis stays in its existing schedule, with that question reserved for a separate administrative hearing. The order encourages retrospective tax relief, but the author says that recommendation has no legal force. Operators in dual-license states that commingle medical and adult-use activity may not qualify. The author also expects litigation over parts of the order, and calls it a step in a longer process rather than a final resolution.

Those limits matter directly for Trulieve because of its uncertain tax position. The liability remains large, with most of it tied to the company's challenge to the trafficking deduction rule for prior tax years. The presentation also notes amended-return refund checks and tax deposits on the balance sheet. It states that any retroactive relief would be recorded as a one-time gain. Market commentary described those liabilities as unresolved.

On broader rescheduling, the presentation says a temporary stay expired in early November and that the company is awaiting an administrative law judge's decision in that proceeding, with a final order possible as soon as this year. That is the company's characterization of the timetable rather than an assured outcome. The company also supports federal banking reform and state-level expansion, including a possible future adult-use path in Pennsylvania.

Cash, Debt and Capital Structure

Cash generation held up. Operating cash flow was close to the prior-year level, while capital expenditures rose substantially, which reduced free cash flow from a year earlier. Investing outflows also included a purchase of intangible assets. Quarter-end cash stood well above the level at the end of last year, even after cash left the group with the Harvest deconsolidation.

Debt is the other side of the ledger. The presentation describes a sizable debt balance at quarter-end carrying a high single-digit interest rate. After the end of the quarter, the company repaid its Mortgage notes on the Jefferson County site ahead of their scheduled maturity, a step that reduces outstanding debt and interest expense.

Corporate changes rounded out the period. Trulieve's domestication from British Columbia to Delaware took effect in August, and the company rang the NYSE closing bell that month to mark its June listing, which it described as the first by a US cannabis company. It was subsequently added to the S&P Total Market Index and the S&P Completion Index, as well as a market data total market index. A share repurchase authorization was also announced earlier in the year.

What Comes Next for the Medical-Only Model

The quarter gave the first full look at Trulieve as a medical-only reporting company, and the main questions now concern execution and policy. Georgia's expansion is under way, the Texas license remains conditional, and capital spending is rising to serve both. Sustaining sequential revenue growth on the comparable basis will be the first measure of whether the expansion can offset the mature nature of the Florida base.

Outside commentary has been more cautious than the company's framing. The market profile, written before these results, described analysts as expecting revenue declines over the next few years and flagged the company's high-interest notes, executive turnover and dependence on regulation as risks. Those points predate the current report and may change as analysts update their work, but they indicate the debate surrounding the shares.

Rivers' framing was that the company is at the beginning of a faster growth phase. Whether that plays out depends on factors partly outside its control: final Texas licensing, the outcome of the broader rescheduling process, and how retroactive tax questions are resolved. For now, the results show a smaller reported business with wider margins, and a tax position that remains the largest unresolved item on the balance sheet.